Literature DB >> 10588409

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity.

J M Gold1, C Queern, V N Iannone, R W Buchanan.   

Abstract

OBJECTIVE: Cognitive impairment is an important feature of schizophrenia and is correlated with functional outcome. However, psychiatry lacks a screening instrument that can reliably assess the types of cognitive impairment often seen in schizophrenia. The authors assessed the sensitivity, convergent validity, and reliability of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as well as the relationship of the RBANS to symptoms and employment status. This newly published test takes 25 minutes to administer and was standardized on a U.S.-Census-matched adult population. The test provides a total score and five index scores, each with a mean value of 100 (SD = 15).
METHOD: RBANS data were obtained from 129 patients with schizophrenia in the outpatient and inpatient programs of the Maryland Psychiatric Research Center. RBANS data were correlated with WAIS-III and Wechsler Memory Scale, 3rd ed. performance in 38 patients. Reliability data for alternate forms of the RBANS were obtained from 53 patients; symptom ratings were obtained from 48 patients; and employment status was examined in 77 patients.
RESULTS: The patients with schizophrenia demonstrated marked impairment on the RBANS (their mean total score was 71.4). The patients' index scores suggested that they had relatively less impairment of language and visual functions than of memory and attention. The RBANS demonstrated high correlations with full-scale IQ and memory measures. The total score demonstrated good reliability. RBANS performance minimally correlated with Brief Psychiatric Rating Scale ratings but was strongly related to employment outcome.
CONCLUSIONS: The RBANS appears to be a useful cognitive screening instrument in schizophrenia. The instrument may be a useful prognostic indicator and offers a means of assessing cognitive status.

Entities:  

Mesh:

Year:  1999        PMID: 10588409     DOI: 10.1176/ajp.156.12.1944

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  81 in total

1.  Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Authors:  Robert W Buchanan; Elaine Weiner; Deanna L Kelly; James M Gold; William R Keller; James A Waltz; Robert P McMahon; David A Gorelick
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

2.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

3.  Neural changes associated with relational learning in schizophrenia.

Authors:  Laura M Rowland; Jacqueline A Griego; Elena A Spieker; Carlos R Cortes; Henry H Holcomb
Journal:  Schizophr Bull       Date:  2010-04-23       Impact factor: 9.306

Review 4.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  A pilot randomized controlled trial of hearing aids to improve mood and cognition in older adults.

Authors:  Katharine K Brewster; Martina Pavlicova; Alexandra Stein; Mei Chen; Chen Chen; Patrick J Brown; Steven P Roose; Ana H Kim; Justin S Golub; Adam Brickman; Jessica Galatioto; Megan Kuhlmey; Bret R Rutherford
Journal:  Int J Geriatr Psychiatry       Date:  2020-04-23       Impact factor: 3.485

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

7.  Neurocognitive and functional correlates of mobile phone use in middle-aged and older patients with schizophrenia.

Authors:  Colin A Depp; Alexandrea L Harmell; Ipsit V Vahia; Brent T Mausbach
Journal:  Aging Ment Health       Date:  2015-03-13       Impact factor: 3.658

8.  Effect of carotid artery stenting on cognitive function in patients with carotid artery stenosis: preliminary results.

Authors:  A S Turk; I Chaudry; V M Haughton; B P Hermann; H A Rowley; K Pulfer; B Aagaard-Kienitz; D B Niemann; P A Turski; R L Levine; C M Strother
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

9.  Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia.

Authors:  Sylvain Grignon; Claire-Anne Grégoire; Myriam Durand; Marie Mury; Dominique Elie; Jean Marc Chianetta
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-25       Impact factor: 4.328

10.  A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Authors:  Irene M Hurford; Stephen R Marder; Richard S E Keefe; Steven P Reise; Robert M Bilder
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.